All News
          tRNA-derived RNA (tDR-1), circulating microbial RNA
Associated w/ reduction in risk of RA conversion in asymptomatic CCP+ individuals (60 vs. 120+ ctrls), 
‼️ tDR-1 alone over performs prediction model w/ smoking shared episode and RF w/ AUC 0.86
What is the mechanism? tDR-1 https://t.co/fuyk4NeOyA
                       
              
          
          
            
              
 
            
          
        
      Links:
             Aurelie Najm AurelieRheumo ( View Tweet)
            
            
          Ribeiro et al. Case series of combination bDMARD/tsDMARD in PsA from Toronto. 24 patients, median just over a year follow-up. Appear effective, especially for objective skin and joint measures. No major safety concerns but short follow-up to date. @RheumNow #ACR25 Abstr#565 https://t.co/Zk3odT2EX2
                      
          
          
            
              
 
            
          
        
      
             Richard Conway RichardPAConway ( View Tweet)
            
            
  
          #0775
Higher circulating microbial small RNA tDR-1 linked to lower risk of developing RA in CCP3+ individuals (AUC 0.86). 
tDR-1 downregulates interferon-response genes in vitro, suggesting microbiome-mediated anti-inflammatory mechanism in RA pathogenesis. @RheumNow #ACR25
        
                Mrinalini Dey DrMiniDey ( View Tweet)
  
          SLE & arthritis: Is there a difference?
 Abstract #0629:
- Non-deforming (ND): 73% | Jaccoud’s: 19% | Rhupus: 8%
- Vs ND, Rhupus had lower odds of type I IFN signature
- Time to deformities: Jaccoud's ~2 yrs vs Rhupus ~5 yrs 
- RNP+ predictive of Jaccoud’s
@RheumNow  #ACR25
        
                Akhil Sood MD, MS AkhilSoodMD ( View Tweet)
  
          Why do some clinics excel at RA disease activity tracking while others struggle? In the VA, success came down to structure: RA-specific clinics, templates, and staff. Barriers? Time, missing labs, and workflow gaps.
@RheumNow #ACR25 Abstract#0222
        
                Jiha Lee JihaRheum ( View Tweet)
          Managing lupus is complex. How do we ensure quality care?
Abstract #0218 convened 8 focus groups:
✅ Support for patient navigators
⚠️ Barriers: low resources, staff turnover
💻 Solution: EHR outreach workflow to flag missed visits & labs
@RheumNow  #ACR25 https://t.co/BWaIMMEPit
                      
          
          
            
              
 
            
          
        
      
             Akhil Sood MD, MS AkhilSoodMD ( View Tweet)
            
            
          Abstract #0607: The age at diagnosis of SLE is rising in US based cohort📈
Those diagnosed ≥30 yrs were:
⬆️ More likely to have oral ulcers, hematologic features, +ANA
⬇️ Less likely to have malar rash or proteinuria
@RheumNow  #ACR25 https://t.co/pMPVLg1xTZ
                      
          
          
            
              
 
            
          
        
      
             Akhil Sood MD, MS AkhilSoodMD ( View Tweet)
            
            
          Damen et al. 10-year follow-up of CRESPA study. Treatment withdrawl trial in early peripheral SpA. 38% in drug free remission. 82% in remission. @RheumNow #ACR25 Abstr#568 https://t.co/KOVW5pSbJg
                      
          
          
            
              
 
            
          
        
      
             Richard Conway RichardPAConway ( View Tweet)
            
            
  
          Abstract 0196: Too many referrals, too few slots? A hybrid RN + MD referral cut wait times for patients with SLE by 26%
Median time to appointment 69 days --> 51 days
Next steps: streamline high-risk triage, reduce manual chart review
@RheumNow #ACR25
        
                Akhil Sood MD, MS AkhilSoodMD ( View Tweet)
          DESIR cohort of early axSpA: 
✳️Factors assoc w/ D2M axSpA - female sex, ⬆️ASDAS-CRP ⬆️BASFI ⬆️ASQOL at baseline. 
✳️ Low prevalence of pts meeting D2M definition (15 pts - 8.4% bDMARD-treated)
#ACR25 @RheumNow Abs0544 https://t.co/fBUh3myKcz
                      
          
          
            
              
 
            
          
        
      
             sheila RHEUMarampa ( View Tweet)
            
            
          Abstract #0189: Rheumatologists are early adopters and high utilizers of #AI scribes.
📊 Adoption: 41%
🧑💻 Retention: 100%
💬 High utilizers (> 70% visits): 83%. The highest among IM subspecialties
🕒 AI scribes reduced EHR time across all measures.
@RheumNow #ACR25 https://t.co/TBurWUKhMl
                      
          
          
            
              
 
            
          
        
      
             Akhil Sood MD, MS AkhilSoodMD ( View Tweet)
            
            
          Ramiro et al. No significant differences seen between men and women in response to upadacitinib in AxSpA at week 14 or 52. Differs from data on TNFi/IL17i in this regard. Looks to me like men respond  a bit quicker and better though... @RheumNow #ACR25 Abstr#589 https://t.co/2m7mrgcG0z
                      
          
          
            
              
 
            
          
        
      
             Richard Conway RichardPAConway ( View Tweet)
            
            
          This retrospective cohort analysis by Dr. Lihi Eder et al showed that among patients with PsA, those w/ high dse activity & high 3VAS scores were assoc w/⬆️ risk of atrial tachyarrythmias. 
Main message: PsA conveys ⬆️CV risk; inflamm control is key!
#ACR25 @RheumNow Abs0522 https://t.co/7sRM7K4V1c
                      
          
          
            
              
 
            
          
        
      
             sheila RHEUMarampa ( View Tweet)
            
            
          In a nationally representative NHANES sample, inflammatory back pain (IBP) was not associated with HLA-B27 positivity or elevated CRP, regardless of IBP criteria used (e.g., Berlin 8a: OR 0.88, p=0.876). IBP alone may be insufficient for identifying axSpA-related immunogenetic or https://t.co/82NjVU171z
                      
          
          
            
              
 
            
          
        
      
             Antoni Chan MD (Prof) synovialjoints ( View Tweet)
            
            
          What can we learn from longitudinal peripheral blood multi-omic profiling in at-risk individuals?
50 RA converters vs. non converters from StopRA study
Decision tree showing highest risk for conversion to clinical RA  in Individuals w/
-CCP3 ≥108 units
-T peripheral helpers https://t.co/jw53EB6tI6
                       
              
          
          
            
              
 
            
          
        
      Links:
             Aurelie Najm AurelieRheumo ( View Tweet)
            
            
          #0774
Multi-omic profiling of anti-CCP3+ “at-risk” individuals reveals Tph & cytotoxic CD8+ expansions, altered gene/chromatin profiles and predictive model (AUC 0.77) for RA conversion
PTPN22 locus accessibility & Tph ≥ 2.45% identify highest risk. @RheumNow #ACR25 https://t.co/JDSMkdmoGv
                      
          
          
            
              
 
            
          
        
      
             Mrinalini Dey DrMiniDey ( View Tweet)
            
            
  
          Not just for salivary glands—lacrimal ultrasound helps too.
In early Sjögren’s, lacrimal + salivary US clearly distinguished SjD from sicca (AUC up to 0.97).
Noninvasive, reproducible, and highly diagnostic.
@RheumNow #ACR25 Abstract #0507
        
                Jiha Lee JihaRheum ( View Tweet)
          A new marker for stratification of ILD in dermatomyositis: Anti MDA5 antibodies!
Japanese study
MDA5 (201-300) positivity associated w/
Lower 6-month progression-free survival (43% vs. 74%)
Lower 5-year survival rates (34% vs. 66%)
Validation in other populations awaited https://t.co/IBiYyATer4
                       
              
          
          
            
              
 
            
          
        
      Links:
             Aurelie Najm AurelieRheumo ( View Tweet)
            
            
          Dr. Werth on the #SLE guidelines on tx of cutaneous LE: 
🔅All patients should be on hydroxychloroquine unless with CI. 
☝️Important! For SLE pts presenting with new-onset rashes, review/ask about medications; consider drug-induced SCLE. 
#ACR25 @RheumNow https://t.co/ok5jAi7uO0
                       
              
          
          
            
              
 
            
          
        
      Links:
             sheila RHEUMarampa ( View Tweet)
            
            
          Getting down with Jack at the @RheumNow #ACR25 stand - come and say hello!
(and Ask Cush Anything - scan the QR code, and maybe end up on the podcast!) https://t.co/0u0boHIIR3
                      
          
          
            
              
 
            
          
        
      
             David Liew drdavidliew ( View Tweet)
            
            
        
    

